Innoviva Inc - Understand $inva stock

$INVA Market Cap: $1.258 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$352.7M

TTM

Gross Margin

87.73%

TTM

Net Earnings

$64.59M

TTM

Current Assets

$400.6M

Q3 2024

Current Liabilities

$223.8M

Q3 2024

Current Ratio

179.05%

Q3 2024

Total Assets

$1.232B

Q3 2024

Total Liabilities

$551.2M

Q3 2024

Book Value

$680.4M

Q3 2024

Cash

$260.6M

Q3 2024

P/E

19.48

Nov 13, 2024 EST

Free Cash Flow

$162.3M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	$310.5M	$331.3M	$1.839M	$1.524M	$5.540M	$261.0M	$217.2M	$133.6M	$53.90M	$8.400M	$4.758M	$135.8M	$24.51M	$24.22M	$24.40M	$23.10M	$22.00M	$19.60M	$12.10M	$8.900M	$3.600M	$200.0K	$0.00
YoY Change	-6.3%	17917.35%	20.67%	-72.49%	-97.88%	20.16%	62.59%	147.87%	541.67%	76.54%	-96.5%	453.84%	1.19%	-0.73%	5.63%	5.0%	12.24%	61.98%	35.96%	147.22%	1700.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	$310.5M	$331.3M	$1.839M	$1.524M	$5.540M	$261.0M	$217.2M	$133.6M	$53.90M	$8.400M	$4.758M	$135.8M	$24.51M	$24.22M	$24.40M	$23.10M	$22.00M	$19.60M	$12.10M	$8.900M	$3.600M	$200.0K	$0.00
Cost Of Revenue	$42.64M	$13.79M
Gross Profit	$267.8M	$317.5M
Gross Profit Margin	86.27%	95.84%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Selling, General & Admin	$98.23M	$63.54M	$16.19M	$13.90M	$14.70M	$22.80M	$32.30M	$23.20M	$19.80M	$34.90M	$48.44M	$30.86M	$30.68M	$27.50M	$27.10M	$28.90M	$35.30M	$32.20M	$23.70M	$23.70M	$14.40M	$16.80M	$20.60M
YoY Change	54.6%	292.52%	16.45%	-5.44%	-35.53%	-29.41%	39.22%	17.17%	-43.27%	-27.95%	56.97%	0.58%	11.57%	1.48%	-6.23%	-18.13%	9.63%	35.86%	0.0%	64.58%	-14.29%	-18.45%	-61.92%
% of Gross Profit	36.68%	20.01%
Research & Development	$33.92M	$41.43M	$576.0K	$1.788M	$0.00	$0.00	$1.355M	$1.400M	$2.600M	$7.500M	$125.2M	$117.9M	$103.6M	$75.07M	$77.50M	$82.00M	$155.3M	$166.6M	$137.9M	$91.60M	$61.70M	$66.50M	$53.80M
YoY Change	-18.13%	7093.06%	-67.79%			-100.0%	-3.21%	-46.15%	-65.33%	-94.01%	6.18%	13.84%	37.96%	-3.14%	-5.49%	-47.2%	-6.78%	20.81%	50.55%	48.46%	-7.22%	23.61%	8.03%
% of Gross Profit	12.67%	13.05%
Depreciation & Amortization	$35.71M	$19.51M	$13.83M	$13.84M	$13.87M	$13.87M	$13.98M	$14.00M	$13.90M	$12.20M	$8.203M	$7.326M	$7.583M	$6.336M	$5.500M	$7.000M	$4.100M	$4.200M	$4.100M	$4.800M	$5.200M	$5.100M	$4.900M
YoY Change	82.99%	41.06%	-0.06%	-0.25%	0.01%	-0.79%	-0.13%	0.72%	13.93%	48.73%	11.97%	-3.39%	19.68%	15.2%	-21.43%	70.73%	-2.38%	2.44%	-14.58%	-7.69%	1.96%	4.08%
% of Gross Profit	13.33%	6.14%
Operating Expenses	$132.2M	$105.0M	$16.76M	$15.67M	$14.66M	$22.75M	$33.61M	$24.60M	$22.40M	$42.40M	$173.6M	$148.8M	$134.2M	$102.5M	$104.6M	$110.9M	$190.6M	$198.8M	$161.6M	$115.3M	$76.10M	$83.20M	$74.40M
YoY Change	25.9%	526.2%	6.97%	6.93%	-35.59%	-32.31%	36.64%	9.82%	-47.17%	-75.58%	16.71%	10.81%	30.92%	-1.96%	-5.68%	-41.82%	-4.12%	23.02%	40.16%	51.51%	-8.53%	11.83%	-28.39%
Operating Profit	$135.7M	$212.6M	$375.1M	$321.1M	$246.4M	$238.3M	$183.6M				-$168.9M	-$13.00M	-$109.7M	-$78.32M
YoY Change	-36.18%	-43.33%	16.81%	30.35%	3.4%	29.76%					1199.05%	-88.15%	40.11%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Interest Expense	$19.16M	$15.79M	$19.07M	$18.33M	$18.66M	$23.95M	$43.60M	-$51.80M	-$51.50M	-$36.30M	$9.348M	$6.003M	$6.022M	$6.044M	-$3.900M	-$400.0K	$8.600M	$13.10M	$6.400M	$3.700M	$1.900M	$3.900M	$9.600M
YoY Change	21.33%	-17.21%	4.03%	-1.76%	-22.1%	-45.06%	-184.17%	0.58%	41.87%	-488.32%	55.72%	-0.32%	-0.36%	-254.97%	875.0%	-104.65%	-34.35%	104.69%	72.97%	94.74%	-51.28%	-59.38%	6.67%
% of Operating Profit	14.12%	7.43%	5.08%	5.71%	7.57%	10.05%	23.75%
Other Income/Expense, Net	-$4.969M	-$3.373M	-$3.626M	-$348.0K	-$345.0K	-$5.702M	-$7.038M	$2.400M	$1.100M	-$3.300M	$6.732M	$0.00	$0.00
YoY Change	47.32%	-6.98%	941.95%	0.87%	-93.95%	-18.98%	-393.25%	118.18%	-133.33%	-149.02%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Pretax Income	$194.1M	$286.9M	$445.3M	$354.2M	$232.9M	$210.3M	$134.3M	$59.50M	-$18.80M	-$73.50M	-$30.60M	-$18.50M	-$115.3M	-$83.90M	-$85.30M	-$93.60M	-$160.0M	-$166.0M	-$143.2M	-$102.7M	-$70.60M	-$79.20M	-$64.80M
YoY Change	-32.36%	-35.56%	25.7%	52.11%	10.77%	56.58%	125.67%	-416.49%	-74.42%	140.2%	65.41%	-83.95%	37.43%	-1.64%	-8.87%	-41.5%	-3.61%	15.92%	39.44%	45.47%	-10.86%	22.22%	-31.72%
Income Tax	$14.38M	$66.69M	$76.44M	$60.43M	$41.90M	-$196.1M	$4.000K		$0.00		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income	7.41%	23.24%	17.17%	17.06%	17.99%	-93.25%	0.0%
Net Earnings	$179.7M	$220.3M	$368.8M	$293.8M	$191.0M	$406.3M	$134.3M	$59.50M	-$18.80M	-$168.5M	-$170.7M	-$18.50M	-$115.3M	-$83.90M	-$85.30M	-$93.60M	-$160.0M	-$166.0M	-$143.2M	-$102.7M	-$70.60M	-$79.20M	-$64.80M
YoY Change	-18.41%	-40.28%	25.53%	53.83%	-53.0%	202.62%	125.67%	-416.49%	-88.84%	-1.29%	822.7%	-83.95%	37.43%	-1.64%	-8.87%	-41.5%	-3.61%	15.92%	39.44%	45.47%	-10.86%	22.22%	-31.72%
Net Earnings / Revenue	57.89%	66.48%	20056.39%	19279.13%	3447.53%	155.68%	61.81%	44.54%	-34.88%	-2005.95%	-3587.64%	-13.63%	-470.38%	-346.37%	-349.59%	-405.19%	-727.27%	-846.94%	-1183.47%	-1153.93%	-1961.11%	-39600.0%
Basic Earnings Per Share	$2.75	$3.07	$3.24	$2.21	$1.55	$3.92	$1.25
Diluted Earnings Per Share	$2.20	$2.37	$2.87	$2.02	$1.43	$3.53	$1.17	$483.0K	-$162.9K	-$1.503M	-$1.667M	-$203.5K	-$1.404M	-$1.164M	-$1.354M	-$1.524M	-$2.645M	-$2.814M	-$2.687M	-$3.084M	-$1.565M	-$1.756M	-$1.437M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Cash & Short-Term Investments	$193.5M	$291.0M	$201.5M	$246.5M	$350.8M	$114.9M	$129.1M	$150.4M	$187.3M	$240.5M	$465.1M	$248.5M	$240.9M	$309.6M	$155.4M	$200.6M	$126.8M	$201.1M	$161.9M	$257.1M	$89.20M	$148.6M
YoY Change	-33.51%	44.42%	-18.25%	-29.73%	205.31%	-11.0%	-14.16%	-19.7%	-22.12%	-48.29%	87.16%	3.15%	-22.19%	99.23%	-22.53%	58.2%	-36.95%	24.21%	-37.03%	188.23%	-39.97%
Cash & Equivalents	$193.5M	$291.0M	$201.5M	$246.5M	$278.1M	$62.40M	$73.30M	$118.0M	$159.2M	$96.80M	$143.5M	$94.80M	$44.80M	$163.3M	$47.50M	$92.30M	$86.40M	$72.40M	$49.80M	$101.4M	$35.70M	$108.8M
Short-Term Investments				$0.00	$72.70M	$52.50M	$55.70M	$32.40M	$28.10M	$143.7M	$321.6M	$153.6M	$196.1M	$146.3M	$107.8M	$108.3M	$40.40M	$128.7M	$112.1M	$155.7M	$53.40M	$39.80M
Other Short-Term Assets	$25.89M	$32.49M	$1.437M	$1.600M	$1.000M	$800.0K	$800.0K	$800.0K	$800.0K	$1.100M	$4.300M	$4.000M	$3.500M	$6.000M	$6.200M	$8.800M	$6.700M	$4.400M	$3.900M	$5.200M	$1.700M	$1.800M
YoY Change	-20.31%	2161.1%	-10.19%	60.0%	25.0%	0.0%	0.0%	0.0%	-27.27%	-74.42%	7.5%	14.29%	-41.67%	-3.23%	-29.55%	31.34%	52.27%	12.82%	-25.0%	205.88%	-5.56%
Inventory	$40.74M	$55.90M								$0.00	$10.40M	$7.500M
Prepaid Expenses
Receivables	$84.08M	$64.07M	$110.7M	$93.90M	$79.40M	$83.30M	$70.50M	$46.80M	$26.20M	$10.60M	$3.400M	$1.100M	$200.0K	$200.0K	$300.0K	$300.0K	$300.0K	$600.0K	$1.000M	$2.100M	$400.0K	$1.500M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$100.0K	$500.0K	$100.0K	$300.0K	$200.0K	$1.200M	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$344.2M	$443.5M	$313.7M	$342.1M	$431.2M	$199.0M	$200.4M	$198.0M	$214.3M	$252.2M	$483.2M	$261.1M	$244.8M	$316.4M	$162.0M	$210.0M	$134.1M	$207.2M	$166.9M	$264.5M	$91.20M	$151.8M
YoY Change	-22.39%	41.39%	-8.31%	-20.66%	116.68%	-0.7%	1.21%	-7.61%	-15.03%	-47.81%	85.06%	6.66%	-22.63%	95.31%	-22.86%	56.6%	-35.28%	24.15%	-36.9%	190.02%	-39.92%
Property, Plant & Equipment	$3.019M	$3.435M	$12.00K	$0.00	$0.00	$200.0K	$200.0K	$400.0K	$200.0K	$300.0K	$10.20M	$9.200M	$10.40M	$10.20M	$12.90M	$16.20M	$20.10M	$15.10M	$13.20M	$13.20M	$15.80M	$20.30M
YoY Change	-12.11%	28525.0%			-100.0%	0.0%	-50.0%	100.0%	-33.33%	-97.06%	10.87%	-11.54%	1.96%	-20.93%	-20.37%	-19.4%	33.11%	14.39%	0.0%	-16.46%	-22.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$561.0M	$403.0M	$483.8M	$438.3M						$42.90M	$55.40M	$95.20M				$0.00	$2.500M	$34.50M	$38.10M
YoY Change	39.2%	-16.71%	10.39%							-22.56%	-41.81%					-100.0%	-92.75%	-9.45%
Other Assets	$3.267M	$4.299M	$17.44M	$94.00M	$154.5M	$196.1M	$0.00	$0.00	$0.00	$18.10M	$8.200M	$3.000M	$3.400M	$4.200M	$5.500M	$8.800M	$3.800M	$3.900M	$4.300M	$5.300M	$8.000M	$10.00M
YoY Change	-24.01%	-75.34%	-81.45%	-39.16%	-21.21%				-100.0%	120.73%	173.33%	-11.76%	-19.05%	-23.64%	-37.5%	131.58%	-2.56%	-9.3%	-18.87%	-33.75%	-20.0%
Total Long-Term Assets	$899.3M	$788.0M	$612.7M	$657.5M	$293.6M	$349.2M	$166.9M	$181.0M	$194.6M	$269.5M	$198.1M	$107.5M	$14.00M	$14.80M	$19.40M	$26.20M	$27.90M	$55.20M	$57.90M	$21.50M	$34.20M	$40.90M
YoY Change	14.12%	28.6%	-6.81%	123.94%	-15.92%	109.23%	-7.79%	-6.99%	-27.79%	36.04%	84.28%	667.86%	-5.41%	-23.71%	-25.95%	-6.09%	-49.46%	-4.66%	169.3%	-37.13%	-16.38%
Total Assets	$1.244B	$1.231B	$926.4M	$999.6M	$724.8M	$548.2M	$367.3M	$379.0M	$408.9M	$521.7M	$681.3M	$368.6M	$258.8M	$331.2M	$181.4M	$236.2M	$162.0M	$262.4M	$224.8M	$286.0M	$125.4M	$192.7M
YoY Change
Accounts Payable	$6.717M	$2.939M	$27.00K	$100.0K	$0.00	$0.00	$600.0K	$100.0K	$800.0K	$0.00	$47.60M	$5.400M	$5.800M	$2.100M	$1.800M	$3.300M	$7.000M	$16.00M	$8.100M	$5.900M	$3.200M	$1.600M
YoY Change	128.55%	10785.19%	-73.0%			-100.0%	500.0%	-87.5%		-100.0%	781.48%	-6.9%	176.19%	16.67%	-45.45%	-52.86%	-56.25%	97.53%	37.29%	84.38%	100.0%
Accrued Expenses	$30.14M	$33.59M	$5.780M	$6.000M	$5.400M	$5.700M	$9.100M	$11.30M	$11.80M	$11.60M	$27.50M	$20.00M	$20.90M	$15.80M	$13.20M	$16.80M	$26.00M	$24.20M	$21.80M	$14.40M	$8.200M	$8.100M
YoY Change	-10.27%	481.11%	-3.67%	11.11%	-5.26%	-37.36%	-19.47%	-4.24%	1.72%	-57.82%	37.5%	-4.31%	32.28%	19.7%	-21.43%	-35.38%	7.44%	11.01%	51.39%	75.61%	1.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$25.00M
YoY Change																					-100.0%
Long-Term Debt Due	$0.00	$96.19M				$0.00	$25.00M	$7.800M	$0.00										$1.200M	$2.400M	$3.100M	$2.800M
YoY Change	-100.0%					-100.0%	220.51%												-50.0%	-22.58%	10.71%
Total Short-Term Liabilities	$38.13M	$135.0M	$5.807M	$6.100M	$5.400M	$5.700M	$34.70M	$20.00M	$13.50M	$13.80M	$84.40M	$30.00M	$45.50M	$40.10M	$38.90M	$44.00M	$55.50M	$59.60M	$48.20M	$33.90M	$20.20M	$39.10M
YoY Change	-71.75%	2224.23%	-4.8%	12.96%	-5.26%	-83.57%	73.5%	48.15%	-2.17%	-83.65%	181.33%	-34.07%	13.47%	3.08%	-11.59%	-20.72%	-6.88%	23.65%	42.18%	67.82%	-48.34%
Long-Term Debt	$446.2M	$444.2M	$394.7M	$385.5M	$377.1M	$382.9M	$574.4M	$708.3M	$733.1M	$725.6M	$287.5M	$172.5M	$172.5M	$172.6M	$172.8M	$172.8M	$400.0K	$500.0K	$600.0K	$1.800M	$4.400M	$7.900M
YoY Change	0.46%	12.55%	2.37%	2.23%	-1.51%	-33.34%	-18.9%	-3.38%	1.03%	152.38%	66.67%	0.0%	-0.06%	-0.12%	0.0%	43100.0%	-20.0%	-16.67%	-66.67%	-59.09%	-44.3%
Other Long-Term Liabilities	$83.62M	$80.79M	$0.00	$100.0K	$200.0K	$600.0K	$900.0K	$3.600M	$5.000M	$5.600M	$10.20M	$11.10M	$127.8M	$141.0M	$158.7M	$154.3M	$172.3M	$139.0M	$116.4M	$59.90M	$33.10M	$10.30M
YoY Change	3.5%		-100.0%	-50.0%	-66.67%	-33.33%	-75.0%	-28.0%	-10.71%	-45.1%	-8.11%	-91.31%	-9.36%	-11.15%	2.85%	-10.45%	23.96%	19.42%	94.32%	80.97%	221.36%
Total Long-Term Liabilities	$529.9M	$525.0M	$394.7M	$385.6M	$377.3M	$383.5M	$575.3M	$711.9M	$738.1M	$731.2M	$297.7M	$183.6M	$300.3M	$313.6M	$331.5M	$327.1M	$172.7M	$139.5M	$117.0M	$61.70M	$37.50M	$18.20M
YoY Change	0.93%	33.02%	2.35%	2.2%	-1.62%	-33.34%	-19.19%	-3.55%	0.94%	145.62%	62.15%	-38.86%	-4.24%	-5.4%	1.35%	89.4%	23.8%	19.23%	89.63%	64.53%	106.04%
Total Liabilities	$568.6M	$665.7M	$511.7M	$459.7M	$411.3M	$394.6M	$610.2M	$732.0M	$751.6M	$745.0M	$382.1M	$213.6M	$345.8M	$353.6M	$370.4M	$371.1M	$228.2M	$199.1M	$165.3M	$95.70M	$57.70M	$57.30M
YoY Change	-14.59%	30.11%	11.3%	11.77%	4.23%	-35.33%	-16.64%	-2.61%	0.89%	94.98%	78.89%	-38.23%	-2.21%	-4.54%	-0.19%	62.62%	14.62%	20.45%	72.73%	65.86%	0.7%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2012	2011	2010
Basic Shares Outstanding	65.44M	69.64M	82.06M	101.3M	101.2M	100.8M	106.9M	110.3M	90.91M shares	82.05M shares	72.07M shares
Diluted Shares Outstanding	86.88M	95.25M	94.31M	113.6M	113.4M	113.4M	119.9M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $1.2583 Billion

About Innoviva Inc

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 112 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The firm's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Industry: Pharmaceutical Preparations Peers: Aclaris Therapeutics Inc AERIE PHARMACEUTICALS INC Amneal Pharmaceuticals Inc Belite Bio Inc Relmada Therapeutics Inc DICE Therapeutics, Inc. Johnson & Johnson REATA PHARMACEUTICALS INC SIGA Technologies Inc